Switzerland clears Pfizer/BioNTech vaccine for 12 to 15-year-olds
Adolescents have the same protection and side effects from the Pfizer/Biontech vaccine as 25-year-olds, studies have shown.
Keystone / Martial Trezzini
The Swiss health regulator Swissmedic has approved the use of the Pfizer/BioNTech vaccine for children aged as young as 12.
This content was published on
1 minute
swissinfo.ch/mga
Tests have shown the vaccine to be close to 100% effective at giving protection against Covid-19 for 12 to 15-year-olds, the agency said on FridayExternal link.
Children in this age group can be given two injections with the same dose as adults, resulting in the same immune response as 16- to 25-year-olds, trials have shown.
The range and severity of side effects proved to be no different between the two age groups: most frequently pain at the injection site, fatigue, headache, shivering, muscle pain, fever and joint pain lasting typically around three days and more pronounced after the second injection.
Last month, regulators in the United States approved the use of the Pfizer/BioNTech vaccine for children as young as 12.
The vaccine roll-out is accelerating in Switzerland. More than five million vaccination doses (Pfizer/BioNTech and Moderna) have been administered so far. Just over 22% of the population has been fully immunised, with another 15.4% having received one jab.
On Friday, the number of new recorded daily infections fell below 500 for the first time since the autumn.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Swisscom receives greenlight for acquisition of Vodafone Italia
This content was published on
The takeover of Vodafone Italia by Swisscom is nearing completion. All relevant authorities have now approved the €8 billion (CHF7.45 billion) deal.
Novo Nordisk stock market plunge drags down Swiss device maker Ypsomed
This content was published on
The Danish pharmaceutical giant, Novo Nordisk, faced setbacks on Friday that weighed on the share price of Swiss injection device manufacturer Ypsomed.
Swiss press react to EU deal with mix of euphoria and scepticism
This content was published on
Swiss media reaction to the agreement between Switzerland and the EU varies widely. Some are celebrating, while others worry about what is to come.
Swiss Solidarity donations to tackle child abuse top CHF4 million
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has raised over CHF4 million ($4.3 million) to tackle child abuse.
EU Commission president says Swiss-EU deal is ‘historic’ agreement
This content was published on
At a joint media conference with Swiss President Viola Amherd in Bern, European Commission President Ursula von der Leyen spoke of a "day of joy".
Switzerland and EU reach deal on future bilateral relations
This content was published on
Switzerland and the European Union have announced a political agreement to update their trading relationship after almost a decade of difficult talks.
This content was published on
At the start of the year, the Swiss authorities were criticised for dragging their heels on vaccinations despite having ambitious targets. Drugs regulator Swissmedic took longer than many countries to approve new vaccines and when they arrived there were large discrepancies between the ability of cantons to administer doses at speed. But this week, Switzerland…
Covid-19: ‘No one will be safe until everyone is safe’
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has launched a new appeal to help those most in need.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.